Pharmacogenomics  	Pharmacogenomics  	 NNP	B-NP
of  	of  	 IN	I-NP
taxane 	taxane 	 CD	I-NP
/ 	/ 	 CD	I-NP
platinum  	platinum  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
Taxane  	Taxane  	 NNP	I-NP
( 	( 	 -LRB-	O
paclitaxel  	paclitaxel  	 NN	B-NP
or  	or  	 CC	O
docetaxel 	docetaxel 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
platinum  	platinum  	 NN	O
( 	( 	 -LRB-	O
cisplatin  	cisplatin  	 NN	B-NP
or  	or  	 CC	O
carboplatin 	carboplatin 	 CD	B-NP
)  	)  	 -RRB-	O
chemotherapy  	chemotherapy  	 NN	O
is  	is  	 VBZ	O
commonly  	commonly  	 RB	O
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
an  	an  	 DT	O
initial  	initial  	 JJ	O
high  	high  	 JJ	O
response  	response  	 NN	O
to  	to  	 TO	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
5-year  	5-year  	 JJ	O
survival  	survival  	 NN	B-NP
rate  	rate  	 NN	I-NP
remains  	remains  	 VBZ	O
low 	low 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	I-NP
pharmacogenomic  	pharmacogenomic  	 JJ	I-NP
markers  	markers  	 NN	I-NP
to  	to  	 TO	O
identify  	identify  	 VB	O
patients  	patients  	 NNS	O
unlikely  	unlikely  	 JJ	O
to  	to  	 TO	O
respond  	respond  	 VB	O
or  	or  	 CC	O
at  	at  	 IN	O
risk  	risk  	 NN	O
for  	for  	 IN	O
severe  	severe  	 JJ	O
toxicity  	toxicity  	 NN	O
will  	will  	 MD	O
assist  	assist  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
goal  	goal  	 NN	O
of  	of  	 IN	O
individualizing  	individualizing  	 JJ	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
Most  	Most  	 JJS	B-NP
studies  	studies  	 NNS	I-NP
have  	have  	 VBP	O
assessed  	assessed  	 VBN	O
single  	single  	 JJ	O
nucleotide  	nucleotide  	 JJ	B-NP
polymorphisms  	polymorphisms  	 NN	I-NP
from  	from  	 IN	O
genes  	genes  	 NNS	O
involved  	involved  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
pharmacokinetics  	pharmacokinetics  	 NN	B-NP
and  	and  	 CC	O
pharmacodynamics  	pharmacodynamics  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
drugs 	drugs 	 NNS	O
.  	.  	 .	O
Unfortunately 	Unfortunately 	 RB	O
,  	,  	 ,	O
most  	most  	 RBS	O
markers  	markers  	 JJ	O
identified  	identified  	 NNS	O
have  	have  	 VBP	O
not  	not  	 RB	O
been  	been  	 VBN	O
replicated  	replicated  	 VBN	O
in  	in  	 IN	O
subsequent  	subsequent  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
Other  	Other  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
of  	of  	 IN	O
variability 	variability 	 NN	O
,  	,  	 ,	O
including  	including  	 VBG	O
epigenetic  	epigenetic  	 JJ	B-NP
control  	control  	 NN	I-NP
of  	of  	 IN	I-NP
gene  	gene  	 NN	I-NP
expression  	expression  	 NN	I-NP
and  	and  	 CC	O
copy  	copy  	 NN	O
number  	number  	 NN	O
variation 	variation 	 NN	O
,  	,  	 ,	O
may  	may  	 MD	O
play  	play  	 VB	O
important  	important  	 JJ	O
roles 	roles 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
nongenetic  	nongenetic  	 NN	B-NP
influences  	influences  	 VBZ	O
such  	such  	 JJ	O
as  	as  	 IN	O
concurrent  	concurrent  	 JJ	O
medications 	medications 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
physiological  	physiological  	 NNS	O
and  	and  	 CC	O
environmental  	environmental  	 JJ	B-NP
factors  	factors  	 NNS	I-NP
could  	could  	 MD	O
also  	also  	 RB	O
affect  	affect  	 VB	O
individual  	individual  	 JJ	B-NP
responses  	responses  	 NNS	I-NP
to  	to  	 TO	O
taxane  	taxane  	 VB	O
and  	and  	 CC	O
platinum  	platinum  	 NN	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
